Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 6/20 | 0.38 |
| ▸ | EP300 | Q09472 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944191 | 0.88 | GAA (0.42) | AR | |
| SCHEMBL943467 | 0.84 | SLC27A1 (0.39) | WNT3A | |
| SCHEMBL942041 | 0.83 | BTK (0.37) | BTKLYNSRCWNT3A | |
| SCHEMBL1645437 | 0.82 | THRB (0.49) | BTKLYNSRCWNT3AEP300 | |
| SCHEMBL941999 | 0.78 | GAA (0.44) | — | |
| SCHEMBL943065 | 0.77 | REV1 (0.43) | — | |
| SCHEMBL942678 | 0.76 | GAA (0.42) | — | |
| SCHEMBL942748 | 0.76 | GAA (0.42) | — | |
| SCHEMBL943058 | 0.76 | MAPT (0.46) | — | |
| SCHEMBL944505 | 0.76 | MT-CO2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524705-B2 | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents | F2G LIMITED BRITISH BODY CORPORATE (GB) | 2013-09-03 | — | — | US | claimed |
| US-20110009390-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2011-01-13 | — | — | US | claimed |
| EP-2173749-B1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-01-12 | — | — | EP | claimed |
| US-8524705-B2 | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents | F2G LIMITED BRITISH BODY CORPORATE (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20110009390-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2173749-B1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009390-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | NAT1, FOXM1, CYP51A1 | BTK 3850/4885LYN 4325/4885SRC 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.